In fact, anti-PD-1/PD-L1 mAbs have received regulatory approval in multiple cancers, including melanoma, lung, kidney, bladder, and head and neck cancers, but they showed minimal activity in CRC (Shrimali et al., 2015). The gene discussed is CD274; the disease is head and neck cancer.